Drug intelligence / Profile preview

WD-920

Development stage: Preclinical
Lead developer: Zhejiang Wenda Pharmaceutical Technology
Modality: Small Molecules

Overview

WD-920 is an investigational small molecule drug candidate developed by Ningbo Wenda Pharmaceutical Technology. It is currently in the preclinical stage of development for the treatment of neurodegenerative disorders, specifically amyotrophic lateral sclerosis (ALS) and Parkinson's disease. As of the current pipeline disclosures, the specific molecular target and mechanism of action for WD-920 have not been publicly revealed, though it represents part of the company's expanding portfolio in central nervous system and oncology indications.

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on WD-920.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-920.

Explore the full profile